Theravance Biopharma (TBPH)
NASDAQ:TBPH
Want to see TBPH full AI Analyst Report?
TBPH Stock Chart & Stats
$17.23
-$0.06(-0.65%)
At close: 4:00 PM EST
$17.23
-$0.06(-0.65%)
Day’s Range― - ―
52-Week Range$8.33 - $21.03
Previous CloseN/A
Volume28.33K
Average Volume (3M)684.19K
Market Cap
$870.75M
Enterprise Value$769.17M
Total Cash (Recent Filing)$315.36M
Total Debt (Recent Filing)$75.50M
Price to Earnings (P/E)3.9
Beta1.11
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.09
Shares Outstanding51,492,924
10 Day Avg. Volume1,272,934
30 Day Avg. Volume684,188
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)3.17
Price to Sales (P/S)8.76
P/FCF Ratio3.95
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue7.16
Enterprise Value/Gross Profit7.54
Enterprise Value/Ebitda930.07
Forecast
1Y Price Target
$16.61Price Target Upside-3.59% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.49
Revenue Forecast (FY)$121.30M
Bulls Say, Bears Say
Bulls Say
Cost Reduction And Cash GenerationSignificant reductions in general and administrative headcount and other cost cuts are designed to sharply lower operating expenses and improve cash burn, supporting a transition to a smaller cash-generating profile.
Patent Protection And LitigationFinal patent settlement resolves outstanding U.S. litigation and clears a major legal obstacle to monetizing Yupelri's U.S. rights, supporting long-term revenue durability.
Strategic Review And MonetizationAn accelerated strategic review is evaluating value‑maximizing and tax‑efficient alternatives, including potential sale or monetization of commercial milestones and profit shares, which could unlock shareholder value.
Bears Say
Clinical Trial FailurePhase 3 CYPRESS trial did not meet its primary endpoint for ampreloxetine, prompting termination of the program and removing a formerly anticipated clinical upside for the company.
Commercialization Delays In ChinaPotential delays in commercial rollout in China due to pricing negotiations could postpone entry into hospital and pharmacy formularies and defer expected revenue contributions from that market.
Pipeline And R&D ContractionWinding down research and development and scaling back the research organization reduces future pipeline investment and limits the company's ability to generate new product-driven growth.
Theravance Biopharma News
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $8.33 and its highest was $21.03 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is $870.75M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Aug 10, 2026 which is in 95 days.
How were Theravance Biopharma’s earnings last quarter?
Currently, no data Available
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Overvalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 51,492,924 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in TBPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theravance Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.61 (-3.59% Downside)
$16.61 (-3.59% Downside)
Blogger Sentiment
Bullish
TBPH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.75%
12-Months-Change
Fundamentals
Return on Equity
46.03%
Trailing 12-Months
Asset Growth
37.10%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
TBPH Stock 12 Month Forecast
Average Price Target
$16.61
▼(-3.59% Downside)
Technical Analysis
Anavex Life Sciences
―
Maravai Lifesciences Holdings
―
Terns Pharmaceuticals
―
Nanobiotix
―
―
Ownership Overview
6.50% Insiders
9.66% Mutual Funds
1.35% Other Institutional Investors
68.81% Public Companies and
Individual Investors